Asset Details
MbrlCatalogueTitleDetail
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
/ Adenine - administration & dosage
/ Adenine - analogs & derivatives
/ Adult
/ AIDS
/ Anti-HIV Agents - administration & dosage
/ Anti-HIV Agents - adverse effects
/ Anti-HIV Agents - therapeutic use
/ Antigens
/ Consent
/ Design
/ Drug Administration Schedule
/ Emtricitabine - administration & dosage
/ Emtricitabine - adverse effects
/ Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - administration & dosage
/ Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination - adverse effects
/ Female
/ Girls
/ HIV
/ HIV Infections - epidemiology
/ HIV Infections - prevention & control
/ Human immunodeficiency virus
/ Humans
/ Injection Site Reaction - epidemiology
/ Injections, Subcutaneous - adverse effects
/ Medication Adherence - statistics & numerical data
/ Outpatient-Based Clinical Medicine
/ Placebos
/ Pre-Exposure Prophylaxis - methods
/ Pre-Exposure Prophylaxis - statistics & numerical data